34 results on '"Hénaut L"'
Search Results
2. IL-8 promotes the calcification of human aortic valve interstitial cells, which is prevented through antagonizing CXCR1 and CXCR2 receptors
- Author
-
Dhayni, K., primary, Chabry, Y., additional, Hénaut, L., additional, Ouled-Haddou, H., additional, Avondo, C., additional, Tribouilloy, C., additional, Caus, T., additional, Zibara, K., additional, Kamel, S., additional, and Bennis, Y., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Impact de l’indoxyl-sulfate sur le développement du rétrécissement aortique calcifié
- Author
-
Candellier, A., primary, Choukroun, G., additional, Grissi, M., additional, Boudot, C., additional, Lenglet, G., additional, Avondo, C., additional, Chillon, J.M., additional, Kamel, S., additional, Brazier, M., additional, and Hénaut, L., additional
- Published
- 2019
- Full Text
- View/download PDF
4. Effets du blocage du récepteur minéralocorticoïde sur l’ischémie cérébrale dans un modèle d’insuffisance rénale chronique chez la souris
- Author
-
Lando, M., primary, Hénaut, L., additional, Grissi, M., additional, Assem, M., additional, Choukroun, G., additional, Kamel, S., additional, and Chillon, J.M., additional
- Published
- 2018
- Full Text
- View/download PDF
5. TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB
- Author
-
Hénaut, L, primary, Sanz, A B, additional, Martin-Sanchez, D, additional, Carrasco, S, additional, Villa-Bellosta, R, additional, Aldamiz-Echevarria, G, additional, Massy, Z A, additional, Sanchez-Nino, M D, additional, and Ortiz, A, additional
- Published
- 2016
- Full Text
- View/download PDF
6. The role of the calcium sensing receptor in the migration of breast cancer cells
- Author
-
Thiem, U., primary, Boudot, C., additional, Lopez, I., additional, Hénaut, L., additional, Clézardin, P., additional, Kamel, S., additional, and Mentaverri, R., additional
- Published
- 2012
- Full Text
- View/download PDF
7. Role of calcium sensing receptor on monocyte migration and vascular calcification related to atherosclerosis
- Author
-
Lopez, I., Henaut, L., Boudot, C., Brazier, M., and Mentaverri, R.
- Published
- 2012
- Full Text
- View/download PDF
8. Association Between Serum Phosphate Levels and Progression of Aortic Stenosis.
- Author
-
Candellier A, Diouf M, Bohbot Y, Bennis Y, Pasquet A, Goffin E, Hénaut L, Choukroun G, Vanoverschelde JL, and Tribouilloy C
- Published
- 2024
- Full Text
- View/download PDF
9. Animal models to study cognitive impairment of chronic kidney disease.
- Author
-
Imenez Silva PH, Pepin M, Figurek A, Gutiérrez-Jiménez E, Bobot M, Iervolino A, Mattace-Raso F, Hoorn EJ, Bailey MA, Hénaut L, Nielsen R, Frische S, Trepiccione F, Hafez G, Altunkaynak HO, Endlich N, Unwin R, Capasso G, Pesic V, Massy Z, and Wagner CA
- Subjects
- Animals, Humans, Mice, Zebrafish, Cognition, Rats, Kidney physiopathology, Kidney metabolism, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic psychology, Renal Insufficiency, Chronic complications, Disease Models, Animal, Cognitive Dysfunction etiology, Cognitive Dysfunction physiopathology, Cognitive Dysfunction psychology
- Abstract
Mild cognitive impairment (MCI) is common in people with chronic kidney disease (CKD), and its prevalence increases with progressive loss of kidney function. MCI is characterized by a decline in cognitive performance greater than expected for an individual age and education level but with minimal impairment of instrumental activities of daily living. Deterioration can affect one or several cognitive domains (attention, memory, executive functions, language, and perceptual motor or social cognition). Given the increasing prevalence of kidney disease, more and more people with CKD will also develop MCI causing an enormous disease burden for these individuals, their relatives, and society. However, the underlying pathomechanisms are poorly understood, and current therapies mostly aim at supporting patients in their daily lives. This illustrates the urgent need to elucidate the pathogenesis and potential therapeutic targets and test novel therapies in appropriate preclinical models. Here, we will outline the necessary criteria for experimental modeling of cognitive disorders in CKD. We discuss the use of mice, rats, and zebrafish as model systems and present valuable techniques through which kidney function and cognitive impairment can be assessed in this setting. Our objective is to enable researchers to overcome hurdles and accelerate preclinical research aimed at improving the therapy of people with CKD and MCI.
- Published
- 2024
- Full Text
- View/download PDF
10. Chronic kidney disease is a key risk factor for aortic stenosis progression.
- Author
-
Candellier A, Bohbot Y, Pasquet A, Diouf M, Vermes E, Goffin E, Gun M, Peugnet F, Hénaut L, Rusinaru D, Mentaverri R, Kamel S, Choukroun G, Vanoverschelde JL, and Tribouilloy C
- Subjects
- Humans, Stroke Volume, Retrospective Studies, Cross-Sectional Studies, Renal Dialysis, Ventricular Function, Left, Aortic Valve surgery, Risk Factors, Glomerular Filtration Rate, Disease Progression, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic therapy, Aortic Valve Stenosis complications, Renal Insufficiency complications
- Abstract
Background: Rapid progression of aortic stenosis (AS) has been observed in patients undergoing dialysis, but existing cross-sectional evidence is contradictory in non-dialysis-dependent chronic kidney disease (CKD). The present study sought to evaluate whether CKD is associated with the progression of AS over time in a large cohort of patients with AS., Methods: We retrospectively studied all consecutive patients diagnosed with AS [peak aortic jet velocity (Vmax) ≥2.5 m/s] and left ventricular ejection fraction ≥50% in the echocardiography laboratories of two tertiary centers between 2000 and 2018. The estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2) was calculated from serum creatinine values. Patients were divided into five CKD stages according to the baseline eGFR. Annual rates of change in the aortic valve area (AVA) were determined by a linear mixed-effects model., Results: Among the 647 patients included, 261 (40%) had CKD. After a median follow-up of 2.9 (interquartile range 1.8-4.8) years, the mean overall rate of change in AVA was -0.077 (95% confidence interval -0.082; -0.073) cm2/year. There was an inverse relationship between the progression rate and kidney function. The more severe the CKD stage, the greater the AVA narrowing (P < .001). By multivariable linear regression analysis, the eGFR was also negatively associated (P < .001) with AS progression. An eGFR strata below 45 mL/min/1.73 m2 was associated with higher odds of rapid progression of AS than normal kidney function. During the clinical follow-up, event-free survival (patients free of aortic valve replacement or death) decreased as CKD progressed. Rapid progression of AS in patients with kidney dysfunction was associated with worse outcomes., Conclusions: Patients with CKD exhibit more rapid progression of AS over time and require close monitoring. The link between kidney dysfunction and rapid progression of AS is still unknown and requires further research., (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2023
- Full Text
- View/download PDF
11. Aortic valve calcification is promoted by interleukin-8 and restricted through antagonizing CXC motif chemokine receptor 2.
- Author
-
Dhayni K, Chabry Y, Hénaut L, Avondo C, Boudot C, Ouled-Haddou H, Bigot-Corbel E, Touati G, Caus T, Messaoudi H, Bellien J, Tribouilloy C, Messika-Zeitoun D, Zibara K, Kamel S, and Bennis Y
- Abstract
Aims: Inflammatory cytokines play a critical role in the progression of calcific aortic valve disease (CAVD), for which there is currently no pharmacological treatment. The aim of this study was to test the hypothesis that interleukin-8 (IL-8), known to be involved in arterial calcification, also promotes aortic valve calcification (AVC) and to evaluate whether pharmacologically blocking the IL-8 receptor, CXC motif chemokine receptor 2 (CXCR2), could be effective in preventing AVC progression., Methods and Results: A cohort of 195 patients (median age 73, 74% men) diagnosed with aortic valve stenosis (severe in 16.9% of cases) were prospectively followed by CT for a median time of 2.6 years. A Cox proportional hazards regression analysis indicated that baseline IL-8 serum concentrations were associated with rapid progression of AVC, defined as an annualized change in the calcification score by CT ≥ 110 AU/year, after adjustment for age, gender, bicuspid anatomy, and baseline disease severity. In vitro, exposure of primary human aortic valvular interstitial cells (hVICs) to 15 pg/mL IL-8 induced a two-fold increase in inorganic phosphate (Pi)-induced calcification. IL-8 promoted NFκB pathway activation, MMP-12 expression, and elastin degradation in hVICs exposed to Pi. These effects were prevented by SCH527123, an antagonist of CXCR2. The expression of CXCR2 was confirmed in hVICs and samples of aortic valves isolated from patients with CAVD, in which the receptor was mainly found in calcified areas, along with MMP-12 and a degraded form of elastin. Finally, in a rat model of chronic kidney disease-associated CAVD, SCH527123 treatment (1 mg/kg/day given orally for 11 weeks) limited the decrease in aortic cusp separation, the increase in maximal velocity of the transaortic jet, and the increase in aortic mean pressure gradient measured by echocardiography, effects that were associated with a reduction in hydroxyapatite deposition and MMP-12 expression in the aortic valves., Conclusion: Overall, these results highlight, for the first time, a significant role for IL-8 in the progression of CAVD by promoting calcification via a CXCR2- and MMP-12-dependent mechanism that leads to elastin degradation, and identify CXCR2 as a promising therapeutic target for the treatment of CAVD., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
12. Relationship between bone marrow adipose tissue and kidney function in postmenopausal women.
- Author
-
Badr S, Cotten A, Mentaverri R, Lombardo D, Labreuche J, Martin C, Hénaut L, Cortet B, and Paccou J
- Abstract
Introduction: Bone marrow adipose tissue (BMAT) is associated with aging, osteoporosis, and chronic kidney disease (CKD). To date, the association between BMAT and kidney function in postmenopausal women has not been thoroughly investigated. The main purpose of this study was to determine whether a relationship exists between proton density fat fraction (PDFF) and kidney function in postmenopausal women., Methods: We investigated the cross-sectional association between estimated glomerular filtration rate (eGFR) - calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation - and PDFF - measured at the lumbar spine and proximal femur using Water Fat Imaging (WFI) MRI - in 199 postmenopausal women from the ADIMOS cohort study. We also performed DXA scans and laboratory measurements of sclerostin and c-terminal Fibroblast Growth Factor 23 (cFGF23)., Results: Participants' mean age was 67.5 (standard deviation, SD 10.0) years. Their median eGFR was 85.0 (interquartile range, IQR 72.2-95.0) ml/min/1.73 cm
2 , and their mean lumbar spine PDFF was 57.9 % (SD 9.6). When classified by eGFR-based CKD stages, 41.7 % of the cohort had an eGFR ≥ 90 ( n = 83), 47.2 % had an eGFR of 60-89.9 ( n = 94), and 11.1 % had an eGFR of 30-59.9 ( n = 22). Participants with eGFR ≥ 90 had a lower lumbar spine PDFF than those with eGFR 60-89.9 (mean 55.8 % (9.8) vs. 58.9 % (9.0), p = 0.031) and those with eGFR 30-59.9 (55.8 % (9.8) vs. 60.8 % (9.8), p = 0.043). However, the differences did not remain significant after adjusting for predetermined confounders, including age, diabetes, Charlson comorbidity index, recent history of fragility fracture, appendicular lean mass, and lumbar spine BMD. The inclusion of sclerostin and/or cFGF23 as suspected mediators did not alter the findings. When proximal hip imaging-based PDFF was considered, no significant differences were found between the eGFR categories in the unadjusted and adjusted analyses., Conclusion: No evidence of an association between kidney function and bone marrow adiposity was found either in the lumbar spine or proximal femur in a cohort of postmenopausal women., Competing Interests: Anne Cotten has received an honorarium from Novartis. Bernard Cortet has received honoraria from Alexion, Amgen, Expanscience, Kyowa-Kirin, MSD, Novartis, Theramex, UCB and Viatris. Julien Paccou has received honoraria from Amgen, MSD, Eli Lilly, Kyowa-Kirin, Theramex and Pfizer. For the remaining authors, none were declared., (© 2023 The Authors. Published by Elsevier Inc.)- Published
- 2023
- Full Text
- View/download PDF
13. Indoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 secretion and the subsequent osteogenic differentiation of human valvular interstitial cells from the aortic valve.
- Author
-
Candellier A, Issa N, Grissi M, Brouette T, Avondo C, Gomila C, Blot G, Gubler B, Touati G, Bennis Y, Caus T, Brazier M, Choukroun G, Tribouilloy C, Kamel S, Boudot C, and Hénaut L
- Subjects
- Humans, Aortic Valve metabolism, NF-kappa B metabolism, Interleukin-6 pharmacology, Indican pharmacology, Indican metabolism, Osteogenesis, Receptors, Aryl Hydrocarbon metabolism, Cells, Cultured, Cell Differentiation, RNA, Small Interfering metabolism, Sulfates metabolism, Sulfates pharmacology, Aortic Valve Stenosis metabolism, Calcinosis metabolism
- Abstract
Background: Calcific aortic stenosis (CAS) is more prevalent, occurs earlier, progresses faster and has worse outcomes in patients with chronic kidney disease (CKD). The uremic toxin indoxyl sulfate (IS) is powerful predictor of cardiovascular mortality in these patients and a strong promoter of ectopic calcification whose role in CAS remains poorly studied. The objective of this study was to evaluate whether IS influences the mineralization of primary human valvular interstitial cells (hVICs) from the aortic valve., Methods: Primary hVICs were exposed to increasing concentrations of IS in osteogenic medium (OM). The hVICs' osteogenic transition was monitored by qRT-PCRs for BMP2 and RUNX2 mRNA. Cell mineralization was assayed using the o-cresolphthalein complexone method. Inflammation was assessed by monitoring NF-κB activation using Western blots as well as IL-1β, IL-6 and TNF-α secretion by ELISAs. Small interfering RNA (siRNA) approaches enabled us to determine which signaling pathways were involved., Results: Indoxyl-sulfate increased OM-induced hVICs osteogenic transition and calcification in a concentration-dependent manner. This effect was blocked by silencing the receptor for IS (the aryl hydrocarbon receptor, AhR). Exposure to IS promoted p65 phosphorylation, the blockade of which inhibited IS-induced mineralization. Exposure to IS promoted IL-6 secretion by hVICs, a phenomenon blocked by silencing AhR or p65. Incubation with an anti-IL-6 antibody neutralized IS's pro-calcific effects., Conclusion: IS promotes hVIC mineralization through AhR-dependent activation of the NF-κB pathway and the subsequent release of IL-6. Further research should seek to determine whether targeting inflammatory pathways can reduce the onset and progression of CKD-related CAS., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Phosphate meeting cholesterol-consequences for cardiovascular disease in chronic kidney disease?
- Author
-
Hénaut L and Massy ZA
- Subjects
- Cholesterol, Humans, Mannosidases, Phosphates, Polysaccharides, Atherosclerosis, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Hyperphosphatemia etiology, Renal Insufficiency, Chronic complications, Vascular Calcification
- Abstract
Cardiovascular disease is highly prevalent in patients with chronic kidney disease. Hyperphosphatemia is associated with subclinical atheromatosis in chronic kidney disease. Phosphate-induced endothelial dysfunction and vascular calcification are thought to be key inducers of atherosclerosis in this condition. Zhou et al. now demonstrate that phosphate promotes de novo cholesterol synthesis in vascular smooth muscle and macrophages through increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activation. This observation may change current concepts of atherosclerosis development and management in chronic kidney disease., (Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease.
- Author
-
Grissi M, Boudot C, Assem M, Candellier A, Lando M, Poirot-Leclercq S, Boullier A, Bennis Y, Lenglet G, Avondo C, Lalau JD, Choukroun G, Massy ZA, Kamel S, Chillon JM, and Hénaut L
- Subjects
- Adenylate Kinase metabolism, Animals, Apoptosis drug effects, Body Weight, Brain Infarction blood, Brain Infarction complications, Brain Infarction drug therapy, Brain Infarction genetics, Enzyme Activation drug effects, Female, Gene Expression Regulation, Gliosis blood, Gliosis complications, Gliosis drug therapy, Infarction, Middle Cerebral Artery blood, Infarction, Middle Cerebral Artery complications, Infarction, Middle Cerebral Artery drug therapy, Infarction, Middle Cerebral Artery genetics, Ischemic Preconditioning, Macrophages drug effects, Macrophages pathology, Metformin blood, Metformin pharmacology, Mice, Inbred C57BL, Microglia drug effects, Microglia pathology, Models, Biological, NF-kappa B metabolism, Neurons drug effects, Neurons pathology, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic genetics, Stroke genetics, Mice, Metformin therapeutic use, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic drug therapy, Stroke drug therapy, Stroke prevention & control
- Abstract
Chronic kidney disease (CKD) worsens ischemic stroke severity in both patients and animals. In mice, these poorer functional outcomes are associated with decreased brain activity of AMP-activated protein kinase (AMPK), a molecule that recently emerged as a potential therapeutic target for ischemic stroke. The antidiabetic drug metformin, a well-known activator of AMPK, has improved stroke outcomes in diabetic patients with normal renal function. We investigated whether chronic metformin pre-conditioning can rescue AMPK activity and prevent stroke damage in non-diabetic mice with CKD. Eight-week-old female C57BL/6J mice were assigned to CKD or SHAM groups. CKD was induced through right kidney cortical electrocautery, followed by left total nephrectomy. Mice were then allocated to receive metformin (200 mg/kg/day) or vehicle for 5 weeks until stroke induction by transient middle cerebral artery occlusion (tMCAO). The infarct volumes were lower in CKD mice exposed to metformin than in vehicle-treated CKD mice 24 h after tMCAO. Metformin pre-conditioning of CKD mice improved their neurological score, grip strength, and prehensile abilities. It also enhanced AMPK activation, reduced apoptosis, increased neuron survival and decreased microglia/macrophage M
1 signature gene expression as well as CKD-induced activation of the canonical NF-κB pathway in the ischemic lesions of CKD mice.- Published
- 2021
- Full Text
- View/download PDF
16. Aortic stenosis in patients with kidney failure: Is there an advantage for a PD-first policy ?
- Author
-
Candellier A, Hénaut L, Morelle J, Choukroun G, Jadoul M, Brazier M, and Goffin É
- Subjects
- Humans, Policy, Quality of Life, Aortic Valve Stenosis, Peritoneal Dialysis adverse effects, Renal Insufficiency
- Abstract
Aortic stenosis (AS) is the most common valvular disease. It is twice as prevalent in patients with kidney failure as compared to the general population. In addition, AS progresses at a faster rate and is associated with a higher risk of death and poorer quality of life in patients on dialysis. Chronic kidney disease-mineral and bone disorder (CKD-MBD), inflammation, and hemodynamic disturbances contribute to the pathophysiology and progression of AS. Whether the type of dialysis modality, that is, hemodialysis (HD) versus peritoneal dialysis (PD), has a differential impact on the development and progression of AS in patients with kidney failure remains debated. Recent data indicate that the prevalence of valvular calcifications might be lower and the development of AS delayed in PD patients, as compared to those treated with HD. This could be accounted for by several mechanisms including reduced valvular shear stress, better preservation of residual kidney function (with better removal of protein-bound uremic toxins and CKD-MBD profile), and lower levels of systemic inflammation. Given the high morbidity and mortality rates related to interventional procedures in the population with kidney failure, surgical and transcatheter aortic valve replacement should be considered in selected patients with severe AS. Strategies slowing down the progression of aortic valve remodeling should remain the cornerstone in the management of individuals with kidney failure and mild to moderate AS. This review explores the potential benefits of PD in patients with kidney failure and AS and provides some clues to help clinicians in the decision-making process when options for kidney replacement therapy are considered in patients with AS.
- Published
- 2021
- Full Text
- View/download PDF
17. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and Personal Preliminary Experience.
- Author
-
Mary A, Hénaut L, Macq PY, Badoux L, Cappe A, Porée T, Eckes M, Dupont H, and Brazier M
- Abstract
The inflammatory response to COVID-19 is specifically associated with an impaired type I interferon (IFN) response and complete blockade of IFN-β secretion. Clinically, nebulization of IFN-α-2b has been historically used in China to treat viral pneumonia associated with SARS-CoV. Very recent data show that the use of inhaled type I IFN is associated with decreased mortality in Chinese COVID-19 patients. However, IFN nebulization is currently not standard in Europe and the United States. Therefore, our group has set up a project aimed to evaluate the possibility to nebulize IFN-β-1b (a drug currently used in Europe to treat multiple sclerosis via subcutaneous injections) and to assess the safety of this new mode of administration in SARS-CoV-2 infected patients. We present here literature data that allowed us to build our hypothesis and to develop collaboration between clinical pharmacists, intensivists and nebulization engineers in order to gain first pre-clinical and clinical experience of IFN-β-1b nebulization. After validation of the nebulization method and verification of droplet size compatible with nebulization, the method has been applied to four intensive care patients treated at our university hospital, for whom none of the COVID-19 therapies initially used in France led to significant clinical improvement. All patients exhibited negative viral carriage and experienced clinical improvement 7-16 days after having initiated nebulized IFN-β-1b inhalation therapy. No side effects were observed. All patients were alive within a 90-days follow-up. Although it is not possible to draw firm conclusions on treatment efficacy based on this case report, our study shows that pulmonary IFN-β-1b administration is feasible, with a good safety profile. This procedure, which presents the advantage of directly targeting the lungs and reducing the risks of systemic side effects, may represent a promising therapeutic strategy for the care of patients with severe COVID-19. However, our preliminary observation requires confirmation by randomized controlled trials., Competing Interests: AM declares travel and accommodation support from Pfizer. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Mary, Hénaut, Macq, Badoux, Cappe, Porée, Eckes, Dupont and Brazier.)
- Published
- 2020
- Full Text
- View/download PDF
18. Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
- Author
-
Mary A, Hénaut L, Schmit JL, Lanoix JP, and Brazier M
- Subjects
- Antimalarials therapeutic use, Humans, Hydroxychloroquine administration & dosage, SARS-CoV-2 isolation & purification, COVID-19 therapy, Interferon Type I administration & dosage, Nebulizers and Vaporizers
- Published
- 2020
- Full Text
- View/download PDF
19. New Insights into the Roles of Monocytes/Macrophages in Cardiovascular Calcification Associated with Chronic Kidney Disease.
- Author
-
Hénaut L, Candellier A, Boudot C, Grissi M, Mentaverri R, Choukroun G, Brazier M, Kamel S, and Massy ZA
- Subjects
- Animals, Humans, Calcinosis immunology, Cardiomyopathies immunology, Macrophages, Monocytes, Renal Insufficiency, Chronic immunology
- Abstract
Cardiovascular disease (CVD) is an important cause of death in patients with chronic kidney disease (CKD), and cardiovascular calcification (CVC) is one of the strongest predictors of CVD in this population. Cardiovascular calcification results from complex cellular interactions involving the endothelium, vascular/valvular cells (i.e., vascular smooth muscle cells, valvular interstitial cells and resident fibroblasts), and monocyte-derived macrophages. Indeed, the production of pro-inflammatory cytokines and oxidative stress by monocyte-derived macrophages is responsible for the osteogenic transformation and mineralization of vascular/valvular cells. However, monocytes/macrophages show the ability to modify their phenotype, and consequently their functions, when facing environmental modifications. This plasticity complicates efforts to understand the pathogenesis of CVC-particularly in a CKD setting, where both uraemic toxins and CKD treatment may affect monocyte/macrophage functions and thereby influence CVC. Here, we review (i) the mechanisms by which each monocyte/macrophage subset either promotes or prevents CVC, and (ii) how both uraemic toxins and CKD therapies might affect these monocyte/macrophage functions., Competing Interests: Z. A. Massy reports grants for CKD REIN and other research projects from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Sanofi-Genzyme, Lilly, Otsuka and the French government, as well as fees and grants to charities from Amgen, and Sanofi-Genzyme. These sources of funding are not necessarily related to the content of the present manuscript.
- Published
- 2019
- Full Text
- View/download PDF
20. Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease.
- Author
-
Hénaut L, Grissi M, Brazier F, Assem M, Poirot-Leclercq S, Lenglet G, Boudot C, Avondo C, Boullier A, Choukroun G, Massy ZA, Kamel S, and Chillon JM
- Subjects
- Adenylate Kinase genetics, Adenylate Kinase metabolism, Animals, Antigens, CD genetics, Antigens, CD metabolism, Apoptosis genetics, Brain Ischemia complications, Brain Ischemia genetics, Brain Ischemia metabolism, Chemokine CCL2 genetics, Chemokine CCL2 metabolism, Disease Models, Animal, Electrocoagulation, Female, Gene Expression Regulation, Humans, Interleukin-1beta genetics, Interleukin-1beta metabolism, Interleukin-6 genetics, Interleukin-6 metabolism, Kidney Cortex pathology, Mice, Mice, Inbred C57BL, Muscle Weakness complications, Muscle Weakness genetics, Muscle Weakness metabolism, NF-kappa B genetics, NF-kappa B metabolism, Neuroglia metabolism, Neuroglia pathology, Neurons pathology, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic genetics, Renal Insufficiency, Chronic metabolism, Rotarod Performance Test, Severity of Illness Index, Stroke complications, Stroke genetics, Stroke metabolism, Brain Ischemia physiopathology, Kidney Cortex metabolism, Muscle Weakness physiopathology, Neurons metabolism, Renal Insufficiency, Chronic physiopathology, Stroke physiopathology
- Abstract
Ischemic stroke is highly prevalent in chronic kidney disease (CKD) patients and has been associated with a higher risk of neurological deterioration and in-hospital mortality. To date, little is known about the processes by which CKD worsens ischemic stroke. This work aimed to investigate the cellular and molecular mechanism associated with ischemic stroke severity in an in vivo model of CKD. CKD was induced through right kidney cortical electrocautery in 8-week-old female C57BL/6 J mice followed by left total nephrectomy. Transient middle cerebral artery occlusion (tMCAO) was performed 6 weeks after left nephrectomy. Twenty-four hours after tMCAO, the infarct volumes were significantly wider in CKD than in SHAM mice. CKD mice displayed decreased neuroscore, impaired ability to remain on rotarod device, weaker muscular strength and decreased prehensile score. Apoptosis, neuronal loss, glial cells recruitment and microglia/macrophages M
1 signature genes CD32, CD86, IL-1β, IL-6, MCP1 and iNOS were significantly increased within ischemic lesions of CKD mice. This effect was associated with decreased AMP kinase phosphorylation and increased activation of the NFΚB pathway. Pharmacological targeting of AMP kinase activity, which is known to block microglia/macrophages M1 polarization, appears promising to improve stroke recovery in CKD.- Published
- 2019
- Full Text
- View/download PDF
21. Activation of the calcium-sensing receptor in human valvular interstitial cells promotes calcification.
- Author
-
Issa H, Hénaut L, Abdallah JB, Boudot C, Lenglet G, Avondo C, Ibrik A, Caus T, Brazier M, Mentaverri R, Zibara K, and Kamel S
- Subjects
- Aortic Valve Stenosis pathology, Calcinosis pathology, Calcium metabolism, Down-Regulation, Humans, Minerals metabolism, Osteogenesis, Receptors, Calcium-Sensing genetics, Tricuspid Valve metabolism, Aortic Valve metabolism, Aortic Valve pathology, Aortic Valve Stenosis metabolism, Calcinosis metabolism, Receptors, Calcium-Sensing metabolism
- Abstract
Introduction and Aims: Calcific aortic valve disease (CAVD) is the most common heart valve disease in western countries. It has been reported that activation of the calcium-sensing receptor(CaSR) expressed by vascular smooth muscle cells prevents vascular calcification. However, to date, the CaSR's expression and function in cardiac valves have not been studied. The present study sought to evaluate the presence of the CaSR within human valvular interstitial cells (hVICs), assess the CaSR's functionality, and ascertain its involvement in hVIC calcification., Methods and Results: Data from Western blot, flow cytometry and immunocytochemistry experiments demonstrated that primary hVICs express the CaSR. The receptor was functional, since the incubation of hVICs with the calcimimetic R-568 significantly increased Ca
2+ -induced ERK1/2 phosphorylation, and exposure to the calcilytic NPS2143 reduced ERK1/2 activation. A reduction in endogenous CaSR expression by hVICs (using siRNA) was associated with significantly lower levels of Ca2+ -induced mineralization (quantified using Alizarin Red staining). Similar data were obtained after the pharmacological inhibition of CaSR activity by the calcilytic NPS2143. In contrast, overexpression of a functional CaSR amplified Ca2+ -induced calcification. Pharmacological activation of the CaSR with the calcimimetic R-568 showed similar effects. CaSR's procalcific properties are associated with increased osteogenic transition (as characterized by elevated mRNA expression of bone morphogenetic protein 2 and osterix), and reduced the expression of the calcification inhibitor osteopontin. Histological analysis of 12 human aortic tricuspid valves showed that CaSR expression was greater in calcified areas than in non-calcified areas. These data were confirmed by Western blots., Conclusions: To the best of our knowledge, this study is the first to have demonstrated that hVICs express a functional CaSR. Taken as a whole, our data suggest that activation of the CaSR expressed by hVICs might be a key promoter of CAVD progression., (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
22. The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders.
- Author
-
Assem M, Lando M, Grissi M, Kamel S, Massy ZA, Chillon JM, and Hénaut L
- Subjects
- Animals, Blood Vessels drug effects, Blood Vessels physiology, Brain blood supply, Brain drug effects, Humans, Microcirculation drug effects, Cerebrovascular Disorders, Cognition Disorders, Toxins, Biological toxicity, Uremia
- Abstract
Individuals at all stages of chronic kidney disease (CKD) have a higher risk of developing cognitive disorders and dementia. Stroke is also highly prevalent in this population and is associated with a higher risk of neurological deterioration, in-hospital mortality, and poor functional outcomes. Evidence from in vitro studies and in vivo animal experiments suggests that accumulation of uremic toxins may contribute to the pathogenesis of stroke and amplify vascular damage, leading to cognitive disorders and dementia. This review summarizes current evidence on the mechanisms by which uremic toxins may favour the occurrence of cerebrovascular diseases and neurological complications in CKD.
- Published
- 2018
- Full Text
- View/download PDF
23. The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function.
- Author
-
Hénaut L, Mary A, Chillon JM, Kamel S, and Massy ZA
- Subjects
- Animals, Humans, Muscle, Smooth, Vascular cytology, Myocytes, Smooth Muscle physiology, Myocytes, Smooth Muscle drug effects, Toxins, Biological toxicity, Uremia
- Abstract
Chronic kidney disease (CKD) is associated with profound vascular remodeling, which accelerates the progression of cardiovascular disease. This remodeling is characterized by intimal hyperplasia, accelerated atherosclerosis, excessive vascular calcification, and vascular stiffness. Vascular smooth muscle cell (VSMC) dysfunction has a key role in the remodeling process. Under uremic conditions, VSMCs can switch from a contractile phenotype to a synthetic phenotype, and undergo abnormal proliferation, migration, senescence, apoptosis, and calcification. A growing body of data from experiments in vitro and animal models suggests that uremic toxins (such as inorganic phosphate, indoxyl sulfate and advanced-glycation end products) may directly impact the VSMCs' physiological functions. Chronic, low-grade inflammation and oxidative stress-hallmarks of CKD-are also strong inducers of VSMC dysfunction. Here, we review current knowledge about the impact of uremic toxins on VSMC function in CKD, and the consequences for pathological vascular remodeling.
- Published
- 2018
- Full Text
- View/download PDF
24. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease.
- Author
-
Hénaut L, Chillon JM, Kamel S, and Massy ZA
- Subjects
- Animals, Anti-Inflammatory Agents therapeutic use, Calcimimetic Agents therapeutic use, Calcium metabolism, Chelating Agents therapeutic use, Fibroblast Growth Factor-23, Fibroblast Growth Factors metabolism, Glucuronidase metabolism, Glycation End Products, Advanced metabolism, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Indican metabolism, Inflammation complications, Inflammation drug therapy, Klotho Proteins, Magnesium therapeutic use, Mesenchymal Stem Cells metabolism, Mesenchymal Stem Cells pathology, Phosphates metabolism, Renal Insufficiency, Chronic complications, Tunica Intima pathology, Tunica Media pathology, Vascular Calcification pathology, Vascular Calcification prevention & control, Vitamin K 2 therapeutic use, Zinc Finger Protein GLI1 metabolism, Cardiovascular Diseases metabolism, Cardiovascular Diseases prevention & control, Renal Insufficiency, Chronic metabolism, Vascular Calcification drug therapy, Vascular Calcification metabolism
- Abstract
In chronic kidney disease (CKD), the progressive decrease in renal function leads to disturbances of mineral metabolism that generally cause secondary hyperparathyroidism. The increase in serum parathyroid hormone is associated with reduced serum calcium and calcitriol levels and/or increased serum fibroblast growth factor-23 and phosphate levels. The resulting CKD-associated disorder of mineral and bone metabolism is associated with various other metabolic dysregulations such as acidosis, malnutrition, inflammation, and accumulation of uremic toxins. It favors the occurrence of vascular calcification, which results from an imbalance between numerous inhibitors and promoters of soft-tissue mineralization. This review provides an overview of the most recent state of knowledge concerning the mechanisms that lead to the development of vascular calcification in the CKD setting. It further proposes directions for potential new therapeutic targets., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
25. Magnesium as a Calcification Inhibitor.
- Author
-
Hénaut L and Massy ZA
- Subjects
- Biomarkers metabolism, Humans, Magnesium therapeutic use, Magnesium Deficiency drug therapy, Magnesium Deficiency metabolism, Renal Insufficiency, Chronic drug therapy, Renal Insufficiency, Chronic metabolism, Urological Agents metabolism, Urological Agents therapeutic use, Vascular Calcification etiology, Vascular Calcification metabolism, Vascular Calcification prevention & control, Magnesium metabolism, Magnesium Deficiency physiopathology, Renal Insufficiency, Chronic physiopathology, Vascular Calcification physiopathology
- Abstract
Vascular calcification (VC) is associated with elevated cardiovascular mortality rates in patients with CKD. Recent clinical studies of patients with advanced CKD have observed an association between low serum magnesium (Mg) levels on one hand and elevated VC and cardiovascular mortality on the other. These findings have stimulated interest in understanding Mg's impact on CKD in general and the associated VC in particular. In vitro and preclinical in vivo data indicate that Mg has the potential to protect vascular smooth muscle cells against calcification via several different molecular mechanisms. Accordingly, data from pilot interventional studies in the clinic suggest that oral Mg supplementation reduces VC in patients with CKD. The present review provides an overview of our current understanding of the impact of Mg on the development of VC in patients with CKD., (Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
26. New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease.
- Author
-
Hénaut L and Massy ZA
- Published
- 2018
- Full Text
- View/download PDF
27. Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation.
- Author
-
Boudot C, Hénaut L, Thiem U, Geraci S, Galante M, Saldanha P, Saidak Z, Six I, Clézardin P, Kamel S, and Mentaverri R
- Abstract
Introduction and Aims: Osteolytic bone metastases are observed in advanced cases of breast cancer. In vitro data suggest that the activity of the calcium-sensing receptor (CaSR) expressed by metastatic cells could potentiate their osteolytic potential. This study aimed to demonstrate in vivo the involvement of the CaSR in breast cancer cells osteolytic potential and to identify potential targets linked to CaSR activity., Methods and Results: MDA-MB-231 stably transfected with plasmids containing either a full-length wild-type CaSR (CaSR-WT), or a functionally inactive dominant negative mutant (CaSR-DN) or an empty vector (EV) were intratibially injected into Balb/c-Nude mice. X-ray analysis performed 19 days after injection showed a dramatic increase of osteolytic lesions in mice injected with CaSR-WT-transfected cells as compared to mice injected with EV- or CaSR-DN-transfected cells. This was associated with decreased BV/TV ratio and increased tumor burden. Epiregulin, an EGF-like ligand, was identified by a DNA microarray as a possible candidate involved in CaSR-mediated osteolysis. Indeed, in vitro , CaSR overexpression increased both epiregulin expression and secretion as compared to EV- or CaSR-DN-transfected cells. Increased epiregulin expression was also detected in osteolytic bone lesions from mice injected with CaSR-WT-transfected MDA-MB-231. In vitro , exposure of osteoblastic cells (HOB and SaOS2) to exogenous epiregulin significantly decreased OPG mRNA expression. Exposure of osteoblastic cells to conditioned media prepared from CaSR-WT-transfected cells also decreased OPG expression. This effect was partially blocked after addition of an anti-epiregulin antibody., Conclusions: Overexpression of a functional CaSR in metastatic breast cancer cells dramatically amplifies their osteolytic potential through epiregulin-mediated OPG downregulation., Competing Interests: CONFLICTS OF INTEREST No conflicts of interest.
- Published
- 2017
- Full Text
- View/download PDF
28. [Professional opportunities for nurses with the rise in pathway coordinator posts].
- Author
-
Hénaut L and Bloch MA
- Subjects
- France, Humans, Career Mobility, Nurse's Role, Patient Navigation
- Abstract
The rapid rise in the number of coordinator posts offers nurses new career and training opportunities. It could also favour a rise in skill levels within the profession and help to transform relations between health care professionals., (Copyright © 2016. Published by Elsevier Masson SAS.)
- Published
- 2016
- Full Text
- View/download PDF
29. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification.
- Author
-
Hénaut L, Sanchez-Nino MD, Aldamiz-Echevarría Castillo G, Sanz AB, and Ortiz A
- Subjects
- Animals, Calcinosis pathology, Calcinosis therapy, Cardiovascular Diseases mortality, Cardiovascular Diseases physiopathology, Cardiovascular Diseases therapy, Cytokines metabolism, Disease Progression, Heart Valve Diseases therapy, Humans, Inflammation complications, Molecular Targeted Therapy, Vascular Calcification therapy, Heart Valve Diseases pathology, Inflammation pathology, Vascular Calcification pathology
- Abstract
Introduction: Cardiac valve calcification and vascular calcification (VC) are associated with cardiovascular mortality in the general population and in patients with chronic kidney disease (CKD). CKD, diabetes mellitus, and atherosclerosis are among the causes of systemic inflammation that are associated with VC., Areas Covered: This review collates clinical and experimental evidence that inflammation accelerates VC progression. Specifically, we review the actions of key pro-inflammatory cytokines and inflammation-related transcription factors on VC, and the role played by senescence. Inflammatory cytokines, such as the TNF superfamily and IL-6 superfamily, and inflammation-related transcription factor NF-κB promote calcification in cultured vascular smooth muscle cells, valvular interstitial cells, or experimental animal models through direct effects, but also indirectly by decreasing circulating Fetuin A or Klotho levels., Expert Opinion: Experimental evidence suggests a causal link between inflammation and VC that would change the clinical approach to prevention and treatment of VC. However, the molecular basis remains unclear and little is known about VC in humans treated with drugs targeting inflammatory cytokines. The effect of biologicals targeting TNF-α, RANKL, IL-6, and other inflammatory mediators on VC, in addition to the impact of dietary phosphate in patients with chronic systemic inflammation, requires study.
- Published
- 2016
- Full Text
- View/download PDF
30. Calcitriol prevents in vitro vascular smooth muscle cell mineralization by regulating calcium-sensing receptor expression.
- Author
-
Mary A, Hénaut L, Boudot C, Six I, Brazier M, Massy ZA, Drüeke TB, Kamel S, and Mentaverri R
- Subjects
- Blotting, Western, Cells, Cultured, Female, Flow Cytometry, Humans, Male, Reverse Transcriptase Polymerase Chain Reaction, Calcitriol pharmacology, Muscle, Smooth, Vascular cytology, Myocytes, Smooth Muscle cytology, Myocytes, Smooth Muscle drug effects, Receptors, Calcium-Sensing metabolism
- Abstract
Vascular calcification (VC) is a degenerative disease that contributes to cardiovascular morbidity and mortality. A negative relationship has been demonstrated between VC and calcium sensing receptor (CaSR) expression in the vasculature. Of interest, vitamin D response elements, which allow responsiveness to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], are present in the promoters of the CaSR gene. We hypothesized that 1,25(OH)2D3, by modulating CaSR expression in vascular smooth muscle cells (VSMCs), might protect against VC. Human VSMCs were exposed to increasing concentrations of 1,25(OH)2D3 (0.01-10 nmol/L) in noncalcifying (1.8 mmol/L) or procalcifying Ca(2+)0 condition (5.0 mmol/L). Using quantitative RT-PCR and Western blotting we observed a significant increase in both CaSR mRNA and protein levels after exposure to 1.0 nmol/L 1,25(OH)2D3. This effect was associated with a maximal increase in CaSR expression at the cell surface after 48 hours of 1,25(OH)2D3 treatment, as assessed by flow cytometry. Down-regulation of the vitamin D receptor by small interfering RNA abolished these effects. In the procalcifying condition, 1.0 nmol/L 1,25(OH)2D3 blocked the Ca(2+)0-induced decrease in total and surface CaSR expression and protected against mineralization. Down-regulation of CaSR expression by CaSR small interfering RNA abolished this protective effect. 1,25(OH)2D3 concentrations of 0.5 and 5.0 nmol/L were also effective, but other (0.01, 0.1, and 10 nmol/L) concentrations did not modify CaSR expression and human VSMC mineralization. In conclusion, these findings suggest that nanomolar concentrations of 1,25(OH)2D3 induce a CaSR-dependent protection against VC. Both lower and higher concentrations are either ineffective or may even promote VC. Whether this also holds true in the clinical setting requires further study.
- Published
- 2015
- Full Text
- View/download PDF
31. [Pathophysiological mechanisms of vascular calcification].
- Author
-
Hénaut L, Mentaverri R, Liabeuf S, Bargnoux AS, Delanaye P, Cavalier É, Cristol JP, Massy Z, and Kamel S
- Subjects
- Humans, Osteoclasts, Vascular Calcification classification, Vascular Calcification complications, Vascular Calcification etiology, Vascular Calcification physiopathology
- Abstract
Vascular calcification (VC) is a degenerative pathology of the vessel wall. In the general population, VC appearance is associated with aging, but this pathology can also develop as a consequence of atherosclerosis, diabetes, inflammatory and chronic kidney disease. VC is strongly associated with increased risk of mortality and cardiovascular disease. Although VC has long been considered as the result of a passive precipitation of mineral, it is now well established that this pathology results from an active and highly regulated cellular process, which shares similarities with bone formation. This review summarizes our current knowledge on VC formation, and details the modalities of action of the main actors known to modulate this process.
- Published
- 2015
- Full Text
- View/download PDF
32. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
- Author
-
Massy ZA, Hénaut L, Larsson TE, and Vervloet MG
- Subjects
- Bone and Bones embryology, Calcimimetic Agents therapeutic use, Cinacalcet, Gastrointestinal Tract metabolism, Homeostasis, Humans, Hyperparathyroidism, Secondary etiology, Hypertension, Pulmonary metabolism, Naphthalenes therapeutic use, Receptors, Calcium-Sensing agonists, Receptors, Calcium-Sensing antagonists & inhibitors, Renal Insufficiency, Chronic complications, Signal Transduction, Vascular Calcification metabolism, Water-Electrolyte Balance, Hyperparathyroidism, Secondary drug therapy, Hyperparathyroidism, Secondary metabolism, Parathyroid Hormone metabolism, Receptors, Calcium-Sensing metabolism, Renal Insufficiency, Chronic metabolism
- Abstract
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease (CKD). Cinacalcet, an allosteric modulator of the calcium-sensing receptor (CaSR) expressed in parathyroid glands, is the only calcimimetic approved to treat SHPT in patients on dialysis. By enhancing CaSR sensitivity for plasma extracellular calcium (Ca(2+)0), cinacalcet reduces serum parathyroid hormone, Ca(2+)0, and serum inorganic phosphorous concentrations, allowing better control of SHPT and CKD-mineral and bone disorders. Of interest, the CaSR also is expressed in a variety of tissues where its activation regulates diverse cellular processes, including secretion, apoptosis, and proliferation. Thus, the existence of potential off-target effects of cinacalcet cannot be neglected. This review summarizes our current knowledge concerning the potential role(s) of the CaSR expressed in various tissues in CKD-related disorders, independently of parathyroid hormone control., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
33. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action.
- Author
-
Hénaut L, Boudot C, Massy ZA, Lopez-Fernandez I, Dupont S, Mary A, Drüeke TB, Kamel S, Brazier M, and Mentaverri R
- Subjects
- Cell Membrane drug effects, Cell Membrane metabolism, Cells, Cultured, Collagen Type I metabolism, Endoplasmic Reticulum drug effects, Endoplasmic Reticulum metabolism, Humans, Muscle, Smooth, Vascular metabolism, Myocytes, Smooth Muscle metabolism, Phenotype, Propylamines, Protein Transport, RNA Interference, Receptors, Calcium-Sensing genetics, Receptors, Calcium-Sensing metabolism, Time Factors, Transfection, Up-Regulation, Vascular Calcification genetics, Vascular Calcification metabolism, Aniline Compounds pharmacology, Biphenyl Compounds pharmacology, Calcimimetic Agents pharmacology, Calcium metabolism, Muscle, Smooth, Vascular drug effects, Myocytes, Smooth Muscle drug effects, Phenethylamines pharmacology, Receptors, Calcium-Sensing drug effects, Vascular Calcification prevention & control
- Abstract
Aims: Vascular calcification (VC) contributes to morbidity and mortality in patients with chronic kidney disease (CKD). Allosteric modulators of the calcium (Ca)-sensing receptor (CaSR) may slow the progression of VC in CKD patients either by reducing serum parathyroid hormone (PTH), Ca, and phosphate levels or by a direct effect on the vessel wall. The aim of this study was to examine the effects of calcimimetics on CaSR expression, cell phenotype, and mineral deposition in human vascular smooth muscle cells (h-VSMCs)., Methods and Results: Primary h-VSMCs were exposed for 14 days to increasing concentrations of Ca(2+) (from 1.8 to 5 mmol/L) in the presence or absence of calcimimetics R-568 or AMG 641 (0.1 μmol/L). Mineralization was detected by Alizarin red staining, and the cell phenotype was assessed using immunocytochemistry and qRT-PCR. CaSR expression was evaluated using flow cytometry. Short- and long-term exposure (1 day to 14 days) of h-VSMCs to calcimimetics promoted CaSR protein transport from the endoplasmic reticulum to the plasma membrane with enhanced CaSR expression on the cell surface, together with an increase in total cell CaSR expression due to enhanced biosynthesis. In pro-mineralizing conditions, exposure to calcimimetics counteracted the Ca(2+)-dependent reduction of CaSR expression, decreased matrix collagen secretion, and mineral deposition by ~90%. These effects involved CaSR activation since it could be inhibited by CaSR siRNA, but not scrambled siRNA., Conclusions: The calcimimetic-dependent increase in biosynthesis and activation of the CaSR in h-VSMCs probably play a key role in the protection against calcium-induced VC.
- Published
- 2014
- Full Text
- View/download PDF
34. Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223.
- Author
-
Rangrez AY, M'Baya-Moutoula E, Metzinger-Le Meuth V, Hénaut L, Djelouat MS, Benchitrit J, Massy ZA, and Metzinger L
- Subjects
- Actin Cytoskeleton genetics, Actin Cytoskeleton metabolism, Animals, Aorta cytology, Aorta drug effects, Aorta metabolism, Apolipoproteins E deficiency, Apolipoproteins E genetics, Cell Proliferation, Down-Regulation drug effects, Gene Expression drug effects, Humans, Kruppel-Like Transcription Factors genetics, Kruppel-Like Transcription Factors metabolism, MADS Domain Proteins genetics, MADS Domain Proteins metabolism, MEF2 Transcription Factors, Mice, Mice, Knockout, MicroRNAs metabolism, Muscle, Smooth, Vascular cytology, Muscle, Smooth, Vascular metabolism, Myocytes, Smooth Muscle cytology, Myocytes, Smooth Muscle metabolism, Myogenic Regulatory Factors genetics, Myogenic Regulatory Factors metabolism, Phosphates pharmacology, Primary Cell Culture, Up-Regulation drug effects, Vascular Calcification genetics, Vascular Calcification metabolism, Versicans genetics, Versicans metabolism, rhoB GTP-Binding Protein genetics, rhoB GTP-Binding Protein metabolism, Cell Movement drug effects, MicroRNAs genetics, Muscle, Smooth, Vascular drug effects, Myocytes, Smooth Muscle drug effects, Phosphates metabolism
- Abstract
Background: An elevated serum inorganic phosphate (Pi) level is a major risk factor for kidney disease and downstream vascular complications. We focused on the effect of Pi levels on human aortic vascular smooth muscle cells (VSMCs), with an emphasis on the role of microRNAs (miRNAs)., Methodology/principal Findings: Exposure of human primary VSMCs in vitro to pathological levels of Pi increased calcification, migration rate and concomitantly reduced cell proliferation and the amount of the actin cytoskeleton. These changes were evidenced by significant downregulation of miRNA-143 (miR-143) and miR-145 and concomitant upregulation of their targets and key markers in synthetic VSMCs, such as Krüppel-like factors-4 and -5 and versican. Interestingly, we also found that miR-223 (a marker of muscle damage and a key factor in osteoclast differentiation) is expressed in VSMCs and is significantly upregulated in Pi-treated cells. Over-expressing miR-223 in VSMCs increased proliferation and markedly enhanced VSMC migration. Additionally, we found that the expression of two of the known miR-223 targets, Mef2c and RhoB, was highly reduced in Pi treated as well as miR-223 over-expressing VSMCs. To complement these in vitro findings, we also observed significant downregulation of miR-143 and miR-145 and upregulation of miR-223 in aorta samples collected from ApoE knock-out mice, which display vascular calcification., Conclusions/significance: Our results suggest that (i) high levels of Pi increase VSMC migration and calcification, (ii) altered expression levels of miR-223 could play a part in this process and (iii) miR-223 is a potential new biomarker of VSMC damage.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.